Results
|
|
1.
|
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. MedStar authors:
- Kurian, Shweta
- Mohebtash, Mahsa
- Ottaviano, Yvonne
- Rao, Suman
- Swain, Sandra M
Year: 2022
Citation: - Breast Cancer Research & Treatment. 196(3):571-581, 2022 Dec.
Institution: - MedStar Franklin Square Medical Center
Department:
- Associate Dean for Research Development
- Hematology/Oncology
- MedStar Health
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Dilawari A, Graham D, Isaacs C, Kurian S, Lynce F, Mainor C, McNamara D, Mohebtash M, Ottaviano Y, Pohlmann PR, Rao S, Swain SM, Swanson N, Tan M, Warren R, Wu T
|
|
|
2.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
|
|
3.
|
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors:
Year: 2019
Citation: - Journal of Clinical Oncology. 37(7):537-546, 2019 03 01.
Institution: - Medstar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J
|
